Tardive Oromandibular Dystonia Induced by Trazodone: A Clinical Case and Management from the Perspective of the Dental Specialist

Toxins (Basel). 2022 Sep 30;14(10):680. doi: 10.3390/toxins14100680.

Abstract

Background: Tardive Oromandibular Dystonia is an iatrogenic drug-induced movement form of extrapyramidal symptoms associated primarily with chronic consumption of dopamine receptor blocking agents. Tardive symptoms attributable to selective serotonin reuptake inhibitors antidepressants are far less prevalent.

Clinical case: The authors will present a clinical case and management, from the dental specialist perspective, of a 55-year-old female patient who developed tardive oromandibular dystonia induced by Trazodone prescribed for sleep insomnia.

Conclusions: Trazodone-induced oromandibular dystonia is extremely rare. Early identification and assessment of tardive symptoms are imperative for successful treatment. Trazodone should be prescribed with caution in patients taking other medications with the potential to cause tardive syndromes.

Keywords: botulinum toxin; oromandibular dystonia; tardive dystonia; trazodone.

Publication types

  • Case Reports

MeSH terms

  • Dystonia* / chemically induced
  • Dystonia* / diagnosis
  • Dystonia* / drug therapy
  • Dystonic Disorders*
  • Female
  • Humans
  • Middle Aged
  • Receptors, Dopamine
  • Selective Serotonin Reuptake Inhibitors / therapeutic use
  • Trazodone* / adverse effects

Substances

  • Trazodone
  • Serotonin Uptake Inhibitors
  • Receptors, Dopamine

Grants and funding

This research received no external funding.